News | January 29, 2022
DCGI approves Bharat Biotech’s Phase 3 trials for intranasal vaccine
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
The vaccines are currently only authorised for emergency use in the country
However, these won’t be available at the nearest chemist store soon
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
It is the generic version of molnupiravir
Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
The product is expected to be available in a week’s time
It plans to deliver over 300 million doses to the Indian government
Subscribe To Our Newsletter & Stay Updated
